Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026)
Protagonist Therapeutics (PTGX) reported Retained Earnings of -$269000.0 for Q1 2026, down 416.47% on a YoY basis from $85000.0 in Q1 2025, and down 141.97% sequentially from $641000.0 in Q4 2025.
Protagonist Therapeutics (PTGX) Retained Earnings (2015 - 2026) Analysis & Trends
Protagonist Therapeutics (PTGX) has 12 years of Retained Earnings data on file, last reported at -$269000.0 in Q1 2026.
- For the quarter ending Q1 2026, Retained Earnings fell 416.47% year-over-year to -$269000.0; the trailing twelve-month figure through Mar 2026 stood at -$269000.0 (down 416.47% YoY), and the FY2025 full-year result was $641000.0, up 100.19% from the prior year.
- Retained Earnings fell to -$269000.0 in Q1 2026, from $641000.0 in the prior quarter.
- In the past five years, Retained Earnings ranged from a high of $641000.0 in Q4 2025 to a low of -$615.7 million in Q4 2023.
- A 5-year average of -$291.4 million and a median of -$408.4 million in 2024 frame the typical range for Retained Earnings.
- Across the five-year window, Retained Earnings plunged 277664.71% in 2024 and surged 100.19% in 2025, its largest moves.
- Tracing PTGX's Retained Earnings over 5 years: stood at -$536.8 million in 2022, then slipped by 14.71% to -$615.7 million in 2023, then soared by 44.69% to -$340.5 million in 2024, then surged by 100.19% to $641000.0 in 2025, then slumped by 141.97% to -$269000.0 in 2026.
- Business Quant data shows PTGX's Retained Earnings at -$269000.0 in Q1 2026, $641000.0 in Q4 2025, and -$426.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Retained Earnings (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -527.87 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -27.89 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 12.91 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | 115.82 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 14.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 11.90 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -622,000.00 |
| 10 | Protagonist Therapeutics | 8.81 Bn | 8.81 Bn | - | -269,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -269,000.00 |
| Dec 31, 2025 | 641,000.00 |
| Sep 30, 2025 | -426.29 Mn |
| Jun 30, 2025 | -15,000.00 |
| Mar 31, 2025 | 85,000.00 |
| Dec 31, 2024 | -340.52 Mn |
| Sep 30, 2024 | -472.20 Mn |
| Jun 30, 2024 | -249,000.00 |
| Mar 31, 2024 | -408.40 Mn |
| Dec 31, 2023 | -615.71 Mn |
| Sep 30, 2023 | -170,000.00 |
| Jun 30, 2023 | -608.90 Mn |
| Mar 31, 2023 | -570.50 Mn |
| Dec 31, 2022 | -536.76 Mn |
| Sep 30, 2022 | -502.60 Mn |
| Jun 30, 2022 | -471.33 Mn |
| Mar 31, 2022 | -472,000.00 |
| Dec 31, 2021 | -409.36 Mn |
| Sep 30, 2021 | -372.50 Mn |
| Jun 30, 2021 | -338.70 Mn |